JY
FBRX icon

Jeff Yass’s Forte Biosciences FBRX Stock Holding History

Jeff Yass’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$304K Sell
14,311
-119,183
-89% -$2.83M ﹤0.01% 11016
2026
Q1 		$3.46M Buy
133,494
+80,580
+152% +$2.32M ﹤0.01% 4977
2025
Q4 		$1.44M Buy
+52,914
New +$928K ﹤0.01% 6350
2024
Q4 		– Sell
-13,096
Closed -$73.3K – 12485
2024
Q3 		$73.3K Buy
13,096
+11,722
+853% +$121K ﹤0.01% 11211
2024
Q2 		$18.4K Buy
+1,374
New +$22.2K ﹤0.01% 11681
2023
Q3 		– Sell
-1,213
Closed -$31.5K – 12271
2023
Q2 		$31.5K Buy
1,213
+800
+194% +$20.8K ﹤0.01% 11498
2023
Q1 		$10.4K Sell
413
-124
-23% -$3.12K ﹤0.01% 12198
2022
Q4 		$13.4K Buy
+537
New +$13.8K ﹤0.01% 11875
2022
Q3 		– Sell
-4,709
Closed -$153K – 13440
2022
Q2 		$153K Buy
4,709
+3,608
+328% +$115K ﹤0.01% 10996
2022
Q1 		$40K Sell
1,101
-1,743
-61% -$66K ﹤0.01% 12401
2021
Q4 		$152K Sell
2,844
-6,125
-68% -$412K ﹤0.01% 11774
2021
Q3 		$664K Buy
+8,969
New +$4.97M ﹤0.01% 8650
2021
Q2 		– Sell
-2,102
Closed -$1.8M – 12742
2021
Q1 		$1.8M Buy
+2,102
New +$1.72M ﹤0.01% 6177
2020
Q4 		– Sell
-180
Closed -$219K – 11190
2020
Q3 		$219K Buy
+180
New +$119K ﹤0.01% 9308
2019
Q4 		– Sell
-170
Closed -$38.5K – 9946
2019
Q3 		$42K Buy
170
+124
+270% +$188K ﹤0.01% 9829
2019
Q2 		$114K Buy
+46
New +$136K ﹤0.01% 9544
2019
Q1 		– Sell
-71
Closed -$274K – 9118
2018
Q4 		$220K Buy
+71
New +$306K ﹤0.01% 7564
2018
Q2 		– Sell
-38
Closed -$139K – 9820
2018
Q1 		$170K Buy
+38
New +$176K ﹤0.01% 8447

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Jeff Yass's FBRX Position: Q2 2026 in Review

Jeff Yass reduced its Forte Biosciences (FBRX) stake by 89% in Q2 2026, selling an estimated $2.83M and leaving 14,311 shares worth $304K. The position accounts for ﹤0.01% of the portfolio, ranked #11016.

Jeff Yass first reported a position in FBRX in Q1 2018 and has held it in 18 quarters since. The position peaked at $3.46M in Q1 2026. 85 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Jeff Yass held 14,311 shares of Forte Biosciences worth $304K as of Q2 2026.
  • Jeff Yass sold 119,183 Forte Biosciences shares in Q2 2026, an estimated $2.83M.
  • Forte Biosciences made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11016 holding.
  • Jeff Yass first reported a position in Forte Biosciences in Q1 2018 and has held it in 18 quarters since.
  • Jeff Yass's Forte Biosciences position peaked at $3.46M in Q1 2026.
  • 85 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.